Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Significant Decline in Short Interest

Key Points

• Short interest plunged 80.8% at Bayer Aktiengesellschaft, falling from 661,820 shares on August 15 to 127,301 shares on August 31. Short interest now represents 0.0% of shares, with a days-to-cover ratio of just 0.2.
• Bayer reported quarterly EPS of $0.29, exceeding estimates by $0.06, while revenue reached $12.53 billion versus the $12.31 billion consensus forecast.
• Analyst sentiment is broadly positive: two analysts rate the stock Strong Buy, five rate it Buy and one rates it Hold, producing a consensus rating of Buy.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the recipient of a large drop in short interest in August. As of August 31st, there was short interest totaling 127,301 shares, a drop of 80.8% from the August 15th total of 661,820 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 724,767 shares, the days-to-cover ratio is presently 0.2 days.

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS:BAYRY opened at $14.07 on Friday. The stock has a market capitalization of $55.30 billion, a P/E ratio of -27.59, a P/E/G ratio of 2.15 and a beta of 0.56. Bayer Aktiengesellschaft has a 1-year low of $7.48 and a 1-year high of $15.23. The company has a current ratio of 1.04, a quick ratio of 0.67 and a debt-to-equity ratio of 1.05. The business has a 50-day moving average price of $14.03 and a two-hundred day moving average price of $12.26.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. The company had revenue of $12.53 billion for the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities analysts predict that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 10th. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a "hold" rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Thursday, July 2nd. Finally, DZ Bank raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Bayer Aktiengesellschaft has a consensus rating of "Buy".

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer's American depositary shares trade over the counter under the symbol BAYRY.

The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women's health, oncology, neurology and specialty therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.